Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
APPLICATION CLOSING DATE: April 13th, 2025 The integration of Artificial Intelligence, mathematical modelling, and advanced computational simulations of biological systems is transforming biomedical
-
meets the following criteria: Recently earned a Ph.D. in bioinformatics, computational biology, computer science, electrical and computer engineering, or a related discipline Strong experience in
-
various disciplines: computer scientists, mathematicians, biologists, chemists, engineers, physicists and clinicians from more than 50 countries currently work at the LCSB. We excel because we are truly
-
range of disciplines in plant biology, including ecology, computational biology, genetics, physiology, biochemistry, cell biology and molecular biology (see www.upsc.se). The postdoctoral scholarship
-
(FSTM) at the University of Luxembourg contributes multidisciplinary expertise in the fields of Mathematics, Physics, Engineering, Computer Science, Life Sciences and Medicine. Through its dual mission
-
The Rantalainen group is focused on application of machine learning and AI for development and validation of predictive models for cancer precision medicine, with a particular focus computational pathology. Our
-
contributing to developing and implementing novel algorithms at the intersection of computational physics and machine learning for the data-driven discovery of physical models. You will be working primarily with
-
program offers a collaborative, multidisciplinary team environment, endowed with a comprehensive support infrastructure. Details regarding the WCM-Q research program and facilities can be accessed at https
-
computational approaches, including artificial intelligence (AI), to unravel the mechanisms driving neuroimmunologic diseases. Your responsibilities: Plan and perform innovative large-scale experiments bridging
-
Doctoral Scientist position. This position will report to Professor Jose Polo, Lead of the Cancer Epigenetics Program at the South Australian Immunogenomics Cancer Institute (SAiGENCI) and the Inaugural